ABEC, a global provider of engineered solutions and services for biotech manufacturing, said that mAbxience will equip their state-of-the-art cGMP facility in León, Spain with an additional ABEC 4,000L CSR bioreactor. Following the successful delivery of the first 4,000L CSR bioreactor in 2021, mAbxience again selected ABEC’s innovative single-use technology to increase its CDMO business and capacity.

In April 2022, and after being approved in Europe, Canada and Japan among others, the U.S. Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for bevacizumab-maly, which was developed by mAbxience and represents the third biosimilar approved in the U.S. Marrying innovation with cutting-edge R&D technology, mAbxience is committed to improving patient access to vital treatments. With the additional 4,000L CSR bioreactor, mAbxience will realize even greater cell culture productivity and faster process transfer scale-up.

“mAbxience’s continued growth in the biosimilar market speaks to the value of our strategic partnerships, such as with ABEC,” said Emmanuelle Lepine, CEO, mAbxience. “As we look to the future of healthcare, we are excited to be on the forefront of sustainable practices that will improve access to critical medicines.”

Scott Pickering, CEO, ABEC, said, “ABEC continues to lead the industry in bringing scale and productivity to single-use manufacturing. We are proud to continue to support mAbxience’s growth with our innovative CSR technology.”